Repurposing approved drugs on the pathway to novel therapies
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The time and cost of developing new drugs have led many groups to limit their search for therapeutics to compounds that have previously been approved for human use. Many “repurposed” drugs, such as derivatives of thalidomide, antibiotics, and antivirals have had clinical success in treatment areas well beyond their original approved use. These include applications in treating antibiotic‐resistant organisms, viruses, cancers and to prevent burn scarring. The major theoretical justification for reusing approved drugs is that they have known modes of action and controllable side effects. Coadministering antibiotics with inhibitors of bacterial toxins or enzymes that mediate multidrug resistance can greatly enhance their activity. Drugs that control host cell pathways, including inflammation, tumor necrosis factor, interferons, and autophagy, can reduce the “cytokine storm” response to injury, control infection, and aid in cancer therapy. An active compound, even if previously approved for human use, will be a poor clinical candidate if it lacks specificity for the new target, has poor solubility or can cause serious side effects. Synergistic combinations can reduce the dosages of the individual components to lower reactivity. Preclinical analysis should take into account that severely ill patients with comorbidities will be more sensitive to side effects than healthy trial subjects. Once an active, approved drug has been identified, collaboration with medicinal chemists can aid in finding derivatives with better physicochemical properties, specificity, and efficacy, to provide novel therapies for cancers, emerging and rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Zhu, Y. X., Kortuem, K. M., & Stewart, A. K. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.728597 · Cited by 293 · cited 1×
“Curiously, its ability to bind to cereblon,(24) a protein involved in limb outgrowth, which is believed to be at the root of its teratogenic effects, may also enable it to control the growth of multiple myeloma cells.(25) More potent derivatives, such as lenalidomide and pomalidomide (Table 1) have been approved by th…”
Background
Cited by
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111615 · Cited by 1,215
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
“Accordingly, the total number of patients taking immunosuppressive drugs has been continuously increasing [2].”
BackgroundDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“376 This shift could lead to unexpected binding to off-target molecules, and the introduction of unforeseen side effects when the drug is administered to humans.”
BackgroundDrug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 257
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“tested their ability to inhibit dengue virus (DENV) replication [118,119].”
Repurposing approved drugs for cancer therapy
Schein, C. H. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldaa045 · Cited by 78
Self-citationBedir, M., Outwin, E., Colnaghi, R., Bassett, L., Abramowicz, I., & O’Driscoll, M. (2024) · EMBO Reports · doi:10.1038/s44319-024-00184-9 · Cited by 6
Metadata
- Authors
- Schein, C. H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2019-08-20
- Volume
- 40
- Issue
- 2
- Pages
- 586-605
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2969609247
- Cited by
- 109
- References
- 2
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.